1
|
Montrucchio G, Alloatti G, Camussi G. Role of platelet-activating factor in cardiovascular pathophysiology. Physiol Rev 2000; 80:1669-99. [PMID: 11015622 DOI: 10.1152/physrev.2000.80.4.1669] [Citation(s) in RCA: 261] [Impact Index Per Article: 10.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023] Open
Abstract
Platelet-activating factor (PAF) is a phospholipid mediator that belongs to a family of biologically active, structurally related alkyl phosphoglycerides. PAF acts via a specific receptor that is coupled with a G protein, which activates a phosphatidylinositol-specific phospholipase C. In this review we focus on the aspects that are more relevant for the cell biology of the cardiovascular system. The in vitro studies provided evidence for a role of PAF both as intercellular and intracellular messenger involved in cell-to-cell communication. In the cardiovascular system, PAF may have a role in embryogenesis because it stimulates endothelial cell migration and angiogenesis and may affect cardiac function because it exhibits mechanical and electrophysiological actions on cardiomyocytes. Moreover, PAF may contribute to modulation of blood pressure mainly by affecting the renal vascular circulation. In pathological conditions, PAF has been involved in the hypotension and cardiac dysfunctions occurring in various cardiovascular stress situations such as cardiac anaphylaxis and hemorrhagic, traumatic, and septic shock syndromes. In addition, experimental studies indicate that PAF has a critical role in the development of myocardial ischemia-reperfusion injury. Indeed, PAF cooperates in the recruitment of leukocytes in inflamed tissue by promoting adhesion to the endothelium and extravascular transmigration of leukocytes. The finding that human heart can produce PAF, expresses PAF receptor, and is sensitive to the negative inotropic action of PAF suggests that this mediator may have a role also in human cardiovascular pathophysiology.
Collapse
Affiliation(s)
- G Montrucchio
- Laboratorio di Immunopatologia Renale, Dipartimento di Medicina Interna, Dipartimento di Biologia Animale e dell'Uomo e Istituto Nazionale di Fisica della Materia, Università di Torino, Torino, Italy
| | | | | |
Collapse
|
2
|
Tetta C, Wratten M, Cristol J, Tarchini R, Bosc J, Canaud B, Camussi G. The Role of Platelet-Activating Factor in the Haemoincompatibility of Haemodialytic Treatments. Int J Artif Organs 1998. [DOI: 10.1177/039139889802101115] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Affiliation(s)
- C. Tetta
- Clinical and Laboratory Research Department, Bellco S.p.A., Mirandola - Italy
| | - M. Wratten
- Clinical and Laboratory Research Department, Bellco S.p.A., Mirandola - Italy
| | - J.P. Cristol
- Departments of Neprology and Biochemistry, Lapeyronie Hospital, Montpellier - France
| | - R. Tarchini
- Department of Nephrology, Carlo Poma Hospital, Mantova
| | - J.Y. Bosc
- Departments of Neprology and Biochemistry, Lapeyronie Hospital, Montpellier - France
| | - B. Canaud
- Departments of Neprology and Biochemistry, Lapeyronie Hospital, Montpellier - France
| | - G. Camussi
- Department of Nephrology, University of Pavia at Varese, Varese - Italy
| |
Collapse
|
3
|
Feuerstein G, Rabinovici R, Leor J, Winkler JD, Vonhof S. Platelet-activating factor and cardiac diseases: therapeutic potential for PAF inhibitors. JOURNAL OF LIPID MEDIATORS AND CELL SIGNALLING 1997; 15:255-84. [PMID: 9041476 DOI: 10.1016/s0929-7855(96)00562-7] [Citation(s) in RCA: 22] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
Platelet-activating factor (PAF) is a potent phospholipid mediator released from inflammatory cells in response to diverse immunologic and non-immunologic stimuli. Animal studies have implicated PAF as a major mediator involved in coronary artery constriction, modulation of myocardial contractility and the generation of arrhythmias which may bear on cardiac disorders such as ischemia, infarction and sudden cardiac death. PAF effects are induced by direct actions of PAF on cardiac tissue to modify chronotropic and inotropic activity, or indirectly via the release of eicosanoids such as thromboxane A2 (TXA2), leukotrienes (LT) or cytokines (TNF alpha). The development of selective, high affinity PAF receptor antagonists has permitted investigations on the role of PAF in experimental animal models of cardiac injury. In vivo and in vitro studies strongly suggest that PAF receptor antagonists might convey therapeutic benefits in ischemic conditions and certain arrhythmias. In addition, PAF antagonists might have a cardiac allograft-preservation effect. Although clinical studies with PAF receptor antagonists in patients with cardiac diseases have not yet been reported, the experimental results to date suggest that PAF receptor antagonists might be useful in some specific cardiac disorders in humans.
Collapse
Affiliation(s)
- G Feuerstein
- Department of Cardiovascular, UW2511, SmithKline Beecham Pharmaceuticals, King of Prussia, PA 19406-0939, USA
| | | | | | | | | |
Collapse
|
4
|
Signal Transduction Pathways Regulating Arachidonic Acid Metabolite Generation Following FcεRI Aggregation. ACTA ACUST UNITED AC 1997. [DOI: 10.1007/978-3-662-22022-1_10] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/15/2023]
|
5
|
Ribbes G, Cane A, Planat V, Breton M, Chap H, Béréziat G, Record M, Colard O. Transacylase-mediated alkylacyl-GPC synthesis and its hydrolysis by phospholipase D occur in separate cell compartments in the human neutrophil. J Cell Biochem 1996; 62:56-68. [PMID: 8836876 DOI: 10.1002/(sici)1097-4644(199607)62:1<56::aid-jcb7>3.0.co;2-0] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
Subcellular localizations of CoA-independent transacylase and phospholipase D enzymes have been investigated in human neutrophils performing a two-step gradient system to separate plasma membranes from internal membranes and from the bulk of granules. The internal membranes were constituted by endoplasmic reticulum and by a subpopulation of specific and tertiary granules. The enzymes activities were assayed in vitro on gradient fractions using exogenous substrates. Following cell prelabelling with [3H]alkyllyso-GPC, we also analyzed the in situ localization of labelled products involving the action of both enzymes. The CoA-independent transacylase activity, together with the CoA-dependent transacylase and acyltransferase activities were only located in the internal membranes. Following 15 min cell labelling, part of the [3H]alkylacyl-GPC was recovered in plasma membranes indicating a rapid redistribution of the acylated compound. Very high contents in arachidonate containing [3H]alkylacyl-GPC were recovered both in plasma membranes and internal membranes. Phospholipase D activity being assayed in the presence of cytosol, GTP gamma S and gradient fractions, only the plasma membrane fractions from resting or stimulated cells allowed the enzyme to be active. The [3H]alkylacyl-GP and [3H]alkylacyl-GPethanol, phospholipase D breakdown products from [3H]alkylacyl-GPC, obtained after neutrophil prelabelling and activation by phorbol myristate acetate, were exclusively present in the plasma membranes. In contrast, the secondary generated [3H]alkylacylglycerols were equally distributed between plasma and internal membranes. No labelled product was recovered on azurophil granules. These data demonstrate that internal membranes are the site of action of the CoA-independent transacylase and plasma membranes are the site of action of the phospholipase D. This topographical separation between CoA-independent transacylase which generated substrate and phospholipase D which degraded it, suggested that subcellular localisation and traffic of substrates within the cell can be important to regulate the enzymes.
Collapse
Affiliation(s)
- G Ribbes
- INSERM Unité 326, Hôpital Purpan, Toulouse, France
| | | | | | | | | | | | | | | |
Collapse
|
6
|
Dentan C, Lesnik P, Chapman MJ, Ninio E. Phagocytic activation induces formation of platelet-activating factor in human monocyte-derived macrophages and in macrophage-derived foam cells. Relevance to the inflammatory reaction in atherogenesis. EUROPEAN JOURNAL OF BIOCHEMISTRY 1996; 236:48-55. [PMID: 8617285 DOI: 10.1111/j.1432-1033.1996.00048.x] [Citation(s) in RCA: 51] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
Monocyte-derived macrophages and macrophage-derived foam cells in arterial tissue may undergo phagocytic activation and thereby contribute to an inflammatory reaction. We have investigated the effect of phagocytic activation on the formation of platelet-activating factor (1-0-alkyl-2-acetyl-sn-glycero-3-phosphocholine, PAF-acether, PAF), a proinflammatory phospholipid, in human monocyte-derived macrophages (macrophages) and in cholesterol-loaded macrophage foam cells (foam cells). Adherent human monocyte-derived macrophages were transformed into foam cells upon incubation with acetylated low-density lipoproteins (Ac-LDL). Such foam cells characteristically displayed a markedly increased content of cholesteryl esters compared with macrophages (4.3 +/- 1.3 microgram/microgram DNA and 0.2 +/- 0.3 microgram/microgram DNA, n = 5, respectively). After phagocytic stimulation with serum-opsonized zymosan (OPZ), both macrophages and foam cells synthesized PAF transiently with maximal production (0.5-1.1 pmol PAF/microgram DNA, n = 5, corresponding to 4.0-8.8 pmol PAF/10(6) cells, as assessed by bioassay) occurring approximately 15 min after stimulation. A major fraction of the synthesized PAF remained cell-associated; such PAF was composed mainly of the hexadecyl (16:0 PAF, approximately 75%) and the octadecenyl (18:1 PAF) species and of trace amounts of octadecyl (18:0 PAF), as assessed by reverse-phase liquid chromatography. Addition of exogenous 16:0 lyso-PAF alone triggered PAF formation (0.9-1.7 pmol PAF/microgram DNA, after 15 min of cellular stimulation); simultaneous cellular stimulation with OPZ and 16:0 lyso-PAF increased PAF formation in an additive manner. Acetyltransferase, the enzyme which acetylates the precursor lyso-PAF and transforms it into PAF, displayed elevated activity both in macrophages and in foam cells, attaining 83-240 pmol PAF formed per min per mg DNA (n = 4); such elevated activity was not increased by OPZ-stimulation. The activity of acetylhydrolase, the PAF-degrading enzyme, was similar in macrophages and in foam cells, and varied between 120 pmol and 320 pmol PAF degraded per min per mg DNA (n = 5). Cell-associated acetylhydrolase activity was increased significantly by 40+/-15 % (P < 0.003, n = 5) after 15 - 30 min of activation with OPZ compared with non-stimulated cells and may account for the rapid decrease in cellular PAF content observed approximately 30 min after stimulation. These studies have established that metabolism of PAF in foam cells closely resembles that in macrophages, and thus PAF metabolism is largely independent of cellular cholesterol content. Moreover our data are consistent with the hypothesis that both macrophages and macrophage-derived foam cells upon phagocytic-activation constitute a significant transient source of PAF at inflammatory sites in the arterial intima where this phospholipidic mediator may exert potent proatherogenic and prothrombotic effects.
Collapse
Affiliation(s)
- C Dentan
- Institut National de la Santé et de la Recherche Médicale U-321, Hôpital de la Pitie, Paris, France
| | | | | | | |
Collapse
|
7
|
Snyder F, Fitzgerald V, Blank ML. Biosynthesis of platelet-activating factor and enzyme inhibitors. ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY 1996; 416:5-10. [PMID: 9131118 DOI: 10.1007/978-1-4899-0179-8_2] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
Platelet-activating factor (PAF) is known to be synthesized by either a remodeling or de novo pathway. The enzymes responsible have been extensively studied by a number of laboratories. All evidence indicates the remodeling route is activated during inflammation and other hypersensitivity responses, whereas the de novo pathway is thought to be the source of PAF required for physiological functions. This article provides an update of what is currently known about the enzymatic systems that generate PAF as well as some preliminary findings we have obtained using potential inhibitors of the specific enzymes involved. Recent progress from our laboratory toward understanding the role of the CoA-independent and Co-A dependent transacylases in the formation of lyso-PAF and PAF is summarized.
Collapse
Affiliation(s)
- F Snyder
- Medical Sciences Division, Oak Ridge Associated Universities, Tennessee37831, USA
| | | | | |
Collapse
|
8
|
Bazan NG, Rodriguez de Turco EB, Allan G. Mediators of injury in neurotrauma: intracellular signal transduction and gene expression. J Neurotrauma 1995; 12:791-814. [PMID: 8594208 DOI: 10.1089/neu.1995.12.791] [Citation(s) in RCA: 161] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023] Open
Abstract
Membrane lipid-derived second messengers are generated by phospholipase A2 (PLA2) during synaptic activity. Overstimulation of this enzyme during neurotrauma results in the accumulation of bioactive metabolites such as arachidonic acid, oxygenated derivatives of arachidonic acid, and platelet-activating factor (PAF). Several of these bioactive lipids participate in cell damage, cell death, or repair-regenerative neural plasticity. Neurotransmitters may activate PLA2 directly when linked to receptors coupled to G proteins and/or indirectly as calcium influx or mobilization from intracellular stores is stimulated. The release of arachidonic acid and its subsequent metabolism to prostaglandins are early responses linked to neuronal signal transduction. Free arachidonic acid may interact with membrane proteins, i.e., receptors, ion channels, and enzymes, modifying their activity. It can also be acted upon by prostaglandin synthase isoenzymes (the constitutive prostaglandin synthase PGS-1 or the inducible PGS-2) and by lipoxygenases, with the resulting formation of different prostaglandins and leukotrienes. Glutamatergic synaptic activity and activation of postsynaptic NMDA receptors are examples of neuronal activity, linked to memory and learning processes, which activate PLA2 with the consequent release of arachidonic acid and platelet-activating factor (PAF), another lipid mediator. Both mediators may exert presynaptic and postsynaptic effects contributing to long-lasting changes in glutamate synaptic efficacy or long-term potentiation (LTP), PAF, a potential retrograde messenger in LTP, stimulates glutamate release. The PAF antagonist BN 52021 competes for receptors in presynaptic membranes and blocks this effect. PAF may also be involved in plasticity responses because PAF leads to the expression of early response genes and subsequent gene cascades. The PAF antagonist BN 50730, selective for PAF intracellular binding, blocks PAF-mediated induction of gene expression. A consequence of neural injury induced by ischemia, trauma, or seizures is an increased release of neurotransmitters, that in turn generates an overproduction of second messengers. Glutamate, a key player in excitotoxic neuronal damage, triggers increased permeation of calcium mediated by NMDA receptors and activation of PLA2 in postsynaptic neurons. NMDA receptor antagonists reduce the accumulation of free fatty acids and elicit neuroprotection in ischemic damage. Increased production of free arachidonic acid and PAF converges to exacerbate glutamate-mediated neurotransmission. These neurotoxic actions may be brought about by arachidonic acid-induced potentiation of NMDA receptor activity and decreased glutamate reuptake. On the other hand, PAF stimulates the further release of glutamate at presynaptic endings. The neuroprotective effects of the PAF antagonist BN 52021 in ischemia-reperfusion are due, at least in part, to an inhibition of presynaptic glutamate release. PAF also induces expression of the inducible prostaglandin synthase gene, and PAF antagonists selective for the intracellular sites inhibit this effect. The PAF antagonist also inhibits the enhanced abundance, due to vasogenic cerebral edema and ischemia-reperfusion damage, of inducible prostaglandin synthase mRNA in vivo. Therefore, PAF, an injury-generated mediator, may favor the formation of other cell injury and inflammation mediators by turning on the expression of the gene that encodes prostaglandin synthase.
Collapse
Affiliation(s)
- N G Bazan
- LSU Neuroscience Center, Louisiana State University Medical Center, New Orleans 70112, USA
| | | | | |
Collapse
|
9
|
Bazan NG, Rodriguez de Turco EB. Platelet-activating factor is a synapse messenger and a modulator of gene expression in the nervous system. Neurochem Int 1995; 26:435-41. [PMID: 7492941 DOI: 10.1016/0197-0186(94)00138-k] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Affiliation(s)
- N G Bazan
- LSU Neuroscience Center, Louisiana State University Medical Center School of Medicine, New Orleans 70112, USA
| | | |
Collapse
|
10
|
Bussolino F, Camussi G. Platelet-Activating Factor Produced by Endothelial Cells. A Molecule with Autocrine and Paracrine Properties. ACTA ACUST UNITED AC 1995. [DOI: 10.1111/j.1432-1033.1995.tb20472.x] [Citation(s) in RCA: 65] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
11
|
Affiliation(s)
- F Snyder
- Medical Sciences Division, Oak Ridge Associated Universities, TN 37831-0117
| |
Collapse
|
12
|
Balsinde J, Fernández B, Solís-Herruzo JA. Increased incorporation of arachidonic acid into phospholipids in zymosan-stimulated mouse peritoneal macrophages. EUROPEAN JOURNAL OF BIOCHEMISTRY 1994; 221:1013-8. [PMID: 8181456 DOI: 10.1111/j.1432-1033.1994.tb18818.x] [Citation(s) in RCA: 26] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
Zymosan, a particle that can be phagocytosed, has been shown to stimulate the release of arachidonic acid (delta 4Ach) in macrophages via a phospholipase-A2-mediated mechanism, and to promote the incorporation of this fatty acid into cellular phospholipids [Balsinde, J., Fernández, B., Solís-Herruzo, J. A. & Diez, E. (1992) Biochim. Biophys. Acta 1136, 75-82]. This work was designed to better understand the regulation of and relationship between these two processes during cellular activation. Initial studies were conducted to examine the incorporation of exogenous [3H]delta 4Ach into the different phospholipid classes. Phosphatidylcholine and phosphatidylinositol initially accounted for most of the radioactivity incorporated into the cell. Prolonged incubation resulted in a decrease in radioactivity in phosphatidylcholine with a concomitant increase in phosphatidylethanolamine. Stimulation of the cells with zymosan led to a remarkable enhancement of the response without changing the pattern of phospholipid acylation by delta 4Ach. In the next series of experiments, the regulatory features of both delta 4Ach release and phospholipid acylation by delta 4Ach in zymosan-treated cells were comparatively investigated. Zymosan-stimulated [3H]delta 4Ach release from previously labeled cells was notably reduced when calcium was absent from the incubation medium and also when the cells were treated with pertussis toxin. Cell treatment with cholera toxin promoted a potentiation of the response. In contrast, neither of these treatments had appreciable effects on zymosan-stimulated [3H]delta 4Ach incorporation into phospholipids. Taken together, these data suggest that zymosan-stimulated delta 4Ach release and phospholipid acylation by delta 4Ach, although closely related, are independently regulated events.
Collapse
Affiliation(s)
- J Balsinde
- Centro de Investigación del Hospital Doce de Octubre, Madrid, Spain
| | | | | |
Collapse
|